Latest from The Tisch Cancer Institute

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Ajai Chari, MD, discusses the impact of the COVID-19 outbreak on hospital protocols and the measures that are being taken to reduce the spread of the virus.

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

Joshua Brody, MD, discusses research with in-situ vaccination in non-Hodgkin lymphoma and strategies being developed to overcome acquired resistance.

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Matthew Galsky, MD, professor of medicine and urology, Hematology and Medical Oncology, director of the Genitourinary Medical Oncology as well as the Novel Therapeutics Unit, and co-director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, provides insight on potentially practice-changing studies in bladder cancer presented at the 2020 Genitourinary (GU) Cancers Symposium.